Abstract
Conventional anti-epileptic treatments have limitations in treating many epileptic patients. Although there have been great advances in the management of epilepsy by application of newly developed anti-convulsants and surgery, some patients still remain in an intractable condition. Other supplementary treatments including immunoglobulin, steroids, and ketogenic diet have significant anti-epileptic potencies. Immunoglobulin treatment shows benefits in some autoimmune-related epileptic conditions such as Rasmussen's encephalitis, however, still has limitations in long-term efficacy. Steroids show significant improvements in many epileptic syndromes including infantile spasm, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spikes and waves during slow wave sleep, however, some of them recur during or after tapering of the drug. Ketogenic diet has become one of the most reliable treatments for intractable epilepsy especially in children. Ketogenic diet is difficult to maintain because of poor palatability, but shows a very high anti-epileptic efficacy. These supplementary treatments should be considered in various epileptic conditions especially in intractable patients.
References
1. Pechadre JC, Sauvezic B, Osier C. Traitment des encephalopathies epileptiques de l'enfant par les immunoglobulines. Rev Electroencephalogr Neurophysiol Clin. 1977. 7:443–447.
2. Ariizumi M, Baba K, Hibio S. Immunoglobulin therapy in the West syndrome. Brain Dev. 1987. 9:422–425.
3. Ariizumi M, Hibio S, Ogawa K, Michihiro N, Shiihara H, Utsumi Y. Comparative study of non-treated and pepsin-treated immunoglobulin therapy for idiopathic Lennox-Gastaut syndrome. Brain Dev. 1984. 6:422–423.
4. Rogers SW, Andrews PI, Gahring LC. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994. 265:648–651.
5. Hart YM, Cortez M, Andermann F. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology. 1994. 44:1030–1036.
6. Snead OC III, Martien KM. Wyllie E, editor. Adrenocorticotropin and steroids. The treatment of epilepsy. 2001. 3rd ed. Philadelphia: Lippincott Williams Wilkins;969–975.
7. Cole AJ, Andermann F, Taylor L. The Landau-Kleffner syndrome of acquired epileptic aphasia: Unusual clinical outcome, surgical experience, and absence of encephalitis. Neurology. 1988. 38:31–38.
8. Lerman P, Lerman-Sagie T, Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol. 1991. 33:257–260.
9. Morikawa T, Seino M, Yagi K. Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P. Long-term outcome of four children with continuous spike-wave during sleep. Epileptic Syndromes in Infancy, Childhood and Adolescence. 1997. 3rd ed. London: John Libbey;257–265.
10. Guelpa G, Marie A. La lutte contre l'epeilepsie par la desintoxication ar par la reeducation alimentair. Revue de Terrapie Medico-Chirurgical. 1911. 78:8–13.
11. Geyelin HR. Fasting as a method for treating epilepsy. Med Rec. 1921. 99:1037–1039.
12. Wilder RM. The effects of ketonemia on the course of epilepsy. Mayo Clin Bull. 1921. 2:307–308.
13. Huttenlocher PR, Wilbourn AJ, Aignore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology. 1971. 21:1097–1103.
16. Keith HM. Convulsive disorders in children with reference to treatment with ketogenic diet. 1963. Boston: Little Brown;176–183.
17. Dekaban AS. Plasma lipids in epileptic children treated with the high fat diet. Arch Neurol. 1966. 15:177–184.
19. DeVivo DC, Leckie MP, Ferrendelli JS, McDougal DB Jr. Chronic ketosis and cerebral metabolism. Ann Neurol. 1978. 3:331–337.
20. Park JC, Kim HD. Benefits of non-fasting ketogenic diet in intractable childhood epilepsy as compared with initial fasting ketogenic diet. Epilepsia. 2001. 42:Suppl 7. 214–215.